DDInter1640 DDInter927
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Saquinavir {u} (Compound) resembles {v} (Compound) Lopinavir
Saquinavir {u} (Compound) resembles {v} (Compound) Nelfinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Saquinavir {u} (Compound) binds {v} (Gene) SLCO1B1
Saquinavir {u} (Compound) upregulates {v} (Gene) UBQLN2
Saquinavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Saquinavir {u} (Compound) downregulates {v} (Gene) COG2
Saquinavir {u} (Compound) causes {v} (Side Effect) Renal failure acute
Saquinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Saquinavir (Compound) resembles Lopinavir (Compound)
Saquinavir (Compound) resembles Nelfinavir (Compound)
Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Saquinavir (Compound) binds SLCO1B1 (Gene)
Saquinavir (Compound) upregulates UBQLN2 (Gene)
Saquinavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Saquinavir (Compound) downregulates COG2 (Gene)
Saquinavir (Compound) causes Renal failure acute (Side Effect)
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin human